Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia

British Journal of Haematology

Volumn 122, Issue 1, 2003, Pages 24-29

  Goulden, Nick ^a   Bader, Peter ^b   Van Der Velden, Vincent ^c   Moppett, John ^a   Schilham, Marco ^d   Masden, Hans O ^e   Krejci, Ondrej ^f   Kreyenberg, Hermann ^b   Lankester, Arjan ^d   Révész, Tom ^g   Klingebiel, Thomas ^h   Van Dongen, Jacques ^c  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Rigshospitalet   (Denmark)

^f UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h GOETHE UNIVERSITY   (Germany)

Author keywords

BMT; Childhood ALL; Ig TCR gene rearrangement PCR; MRD; Relapse

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC RESTRICTION; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; HIGH RISK POPULATION; HUMAN; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; TREATMENT INDICATION;

BONE MARROW TRANSPLANTATION; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; NEOPLASM, RESIDUAL; PATIENT SELECTION; PROGNOSIS; RECURRENCE;

EID: 0038007444     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04394.x     Document Type: Article

References (20)

1. Bader, P., Hancock, J., Kreyenberg, H., Goulden, N.J., Niethammer, D., Oakhill, A., Steward, C.G., Handgretinger, R., Beck, J.F. & Klingebiel, T. (2002) Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia, 16, 1668-1672.
2. Borgmann, A., Baumgarten, E., Schmid, H., Dopfer, R., Ebell, W., Göbel, U., Niethammer, D., Gadner, H. & Henze, G. (1997) Allogeneic bone marrow transplantation for a subset of children with acute lymphoblastic leukemia in third remission: a conceivable alternative? Bone Marrow Transplantation, 20, 939-944.
3. Cavé, H., van der Werff ten Bosch, J., Suciu, S., Guidal, C., Waterkeyn, C., Otten, J., Bakkus, M., Thielemans, K., Grandchamp, B. & Vilmer, E. (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. New England Journal of Medicine, 339, 591-598.
4. Chessells, J.M. (1998) Relapsed lymphoblastic leukaemia in children: a continuing challenge. British Journal of Haematology. 102, 423-438.
5. Chessells, J.M. (2000) The management of high-risk lymphoblastic leukaemia in children. British Journal of Haematology, 108, 204-216.
6. van Dongen, J.J.M., Seriu, T., Panzer-Grümayer, E.R., Biondi, A., Pongers-Willemse, M.J., Corral, L., StoLz, F., Schrappe, M., Masera, G., Kamps, W.A., Gadner, H., van Wering, E.R., Ludwig, W.-D., Basso, G., de Bruijn, M.A.C., Cazzaniga, G., Hettinger, E., van der Does-van den Berg, A., Hop, W.C.J., Riehm, H. & Bartram, C.R. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia. Lancet, 352, 1731-1738.
7. Eckert, C., Biondi, A., Seeger, K., Cazzaniga, G., Hartmann, R., Beyermann, B., Pogodda, M., Proba, J. & Henze, G. (2001) Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet. 358, 1239-1241.
8. Handgretinger, R., Klingebiel, T., Lang, P., Schumm, M., Neu, S., Geiselhart, A., Bader, P., Schlegel, P.G., Greil, J., Stachel, D., Herzog, R.J. & Niethammer, D. (2001) Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplantation, 27, 777-783.
9. Heslop, H.E. (1999) Haemopoietic stem cell transplantation from unrelated donors. British Journal of Haematology, 105, 2-6.
10. Knechtli, C.J., Goulden, N.J., Hancock, J.P., Grandage, V.L., Harris, E.L., Garland, R.J., Jones, C.G., Rowbottom, A.W., Hunt, L.P., Green, A.F., Clarke, E., Lankester, A.W., Cornish, J.M., Pamphilon, D.H., Steward, C.G. & Oakhill, A. (1998) Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood, 92, 4072-4079.
11. Moppett, J., Goulden, N.J., Darbyshire, P.J., Steward, C.G., Hancock, J., Garland, R.J., Burke, G.A.A., Groves, S., Pamphilon, D., Cornish, J. & Oakhill, A. (2001) Additional cytoreduction pretransplant for MRD positive children with ALL in CR2: feasibility and outcome. Blood, 98, 386b.
12. Nyvold, C., Madsen, H.O., Ryder, L.P., Seyfarth, J., Sveigaard, A., Clausen, N., Wesenberg, F., Jonsson, O.G., Forestier, E. & Schmiegelow, K. (2002) Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood, 99, 1253-1258.
13. Seeger, K., Adams, H.P., Buchwald, D., Beyermann, B., Kremens, B., Niemeyer, C., Ritter, J., Schwabe, D., Harms, D., Schrappe, M. & Henze, G. (1998) Tel-AML 1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Münster Study Group. Blood, 91, 1716-1722.
14. zur Stadt, U., Harms, D.O., Schluter, S., Schrappe, M., Goebel, U., Spaar, H., Janka, G. & Kabisch, H. (2001) MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen. Leukemia, 15, 283-285.
15. Szczepanski, T., van der Velden, V.H.J. & van Dongen, J.J.M. (2002) Real-time quantitative (RQ)-PCR for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Haematologica, 87, 183-191.
16. van der Velden, V.H.J., Joosten, S.A., Willemse, M.J., van Wering. E.R., Lankester, A.W., van Dongen, J.J.M. & Hoogerbrugge, P.M. (2001) Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia. Leukemia, 15, 1485-1487.
17. van der Velden, V.H.J., Willemse, M.J., van der Schoot, C.E., van Wering, E.R. & van Dongen, J.J.M. (2002a) Immunoglobulin kappa deleting element rearrangements in precursor-B-acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia, 16. 928-936.
18. van der Velden, V.H.J., Wijkhuijs, J.M., Jacobs, D.C.H., van Wering, E.R. & van Dongen, J.J.M. (2002b) T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia, 16, 1372-1380.
19. Verhagen, O., Willemse, M., Breunis, W., Wijkhuis, A., Jacobs, D., Joosten, S., van Wering, E., van Dongen, J.J.M. & van der Schoot, C. (2000) Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia, 14, 1426-1435.
20. Wheeler, K., Richards, S., Bailey, C. & Chessells, J. (1998) Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. British Journal of Haematology, 101, 93-102.